HA vs Polynucleotide vs Exosome Skin Boosters Explained

TL;DR: Skin boosters fall into three ingredient classes: hyaluronic acid, polynucleotide, and exosome, and each one targets a different skin problem with a different depth of clinical evidence behind it. Hyaluronic acid boosters work on hydration and surface texture with results measured at one and six months. Polynucleotide boosters work on the dermis itself over a course of sessions spaced weeks apart, backed by a modest but growing set of studies. Exosome injections remain in an early research stage, and in Korea most exosome products sold today are registered as cosmetics, which means injecting them is not a legally recognized use.

We hear some version of the same question in almost every consultation at our Gangnam clinic: which is better, Rejuran, a hyaluronic acid booster, or an exosome treatment. The honest answer is that these are not three tiers of the same treatment. They are three separate ingredient classes aimed at three separate problems, and only two of them currently have a clear legal path into the skin in Korea. Before we ever discuss a product name, we ask two things: what the skin is actually missing right now, and whether the product under discussion is even authorized to be injected here.

We already laid out the difference between hyaluronic acid and polynucleotide boosters in detail in our comparison of Rejuran and HA skin boosters. This article picks up where that one stopped: where exosomes sit on this map, and why our treatment list at UH CELL Gangnam does not include exosome injections.

Three Questions Separate the Classes

All three ingredients get grouped under the same “skin booster” label, but three distinct questions actually decide which one applies.

The first is the target problem. Dryness at the surface with dull, rough texture is a different issue from thinning dermal density that shows up as fine lines and reduced bounce. The second is mechanism. Some ingredients work by physically holding water in place. Others send a signal that prompts the skin’s own cells to respond, and that difference changes both how fast results show up and when you should expect to evaluate them. The third question, and the one skipped most often in casual conversation, is what evidence exists and whether the product is legally authorized for injection into skin in the country where the patient is being treated.

That third question rarely comes up in general skincare talk, but it decides whether the first two questions are even worth asking.

Hyaluronic Acid Boosters: Hydration and Texture

Hyaluronic acid boosters place small microdroplets of hyaluronic acid across many points in the dermis. The ingredient itself is the same one used in volumizing fillers, but the goal is different: instead of shaping contour, the injection targets the skin’s ability to hold water, which shows up as smoother texture and a healthier surface glow.

SKINVIVE by JUVÉDERM, built on the ingredient VYC-12L, is one product in this class with published trial data. Allergan Aesthetics announced FDA approval of the product for cheek skin smoothness in adults over 21 in May 2023. In the randomized, multicenter, evaluator-blinded pivotal trial behind that approval, Practical Dermatology reported in 2023 that 58 percent of subjects showed at least a one-point improvement on a cheek smoothness scale at the one-month mark, with 56 percent still showing that improvement at six months. Allergan Aesthetics has said results hold through six months with optimal treatment. In June 2026, the company announced an expanded approval covering horizontal neck lines, the product’s second indication.

Read plainly, those numbers describe an improvement in just over half of patients, not a dramatic transformation. We say that directly in consultation. Hyaluronic acid boosters tend to act relatively quickly and carry a light recovery burden, with a modest scale of change. Formulations containing lidocaine keep discomfort manageable during treatment, and product safety information lists swelling, redness, bruising, and small nodules at the injection site as the typical reactions.

Polynucleotide Boosters: Working on the Dermis Itself

Polynucleotide boosters use purified DNA fragments, typically sourced from salmon, refined into an oligonucleotide mixture and injected into the dermis. The goal is to prompt fibroblasts to respond, which changes the composition of the dermis over time, a different point of action from hyaluronic acid holding water at the injection site. The meaningful comparison point falls after a full course of sessions spaced roughly four weeks apart.

One of the more clearly designed studies in this class comes from Ting Song Lim and colleagues, published in Clinical, Cosmetic and Investigational Dermatology in 2024. The study followed 30 Asian participants with a mean age of 40.2 years through three dermal injections of a high-purification-technology polynucleotide, at baseline, four weeks, and eight weeks, with follow-up extending to four and six months. Using three-dimensional skin analysis alongside a global aesthetic improvement scale, the researchers found statistically significant improvement in surface uniformity, elasticity, pigmentation, and radiance, with no early or late adverse events reported.

The evidence base for the class overall is still being built out. A systematic review led by Smaragda Lampridou of Imperial College London, with co-authors Sian Bassett, Maurizio Cavallini, and George Christopoulos, published in the Journal of Cosmetic Dermatology in 2025, searched English-language literature from January 2010 through January 2024 and included just nine studies covering a combined 219 participants. The authors rated the included studies as low to moderate quality and concluded that standardized study designs, larger samples, and longer follow-up periods are still needed.

A combined sample of 219 across nine studies tells you where to set your expectations. When we recommend this class, we agree on the session schedule and the evaluation point before the first injection, because a single session followed by a mirror check the next morning is not how this treatment is designed to be judged.

Where Exosome Treatments Actually Stand

Exosomes are nanoscale vesicles secreted by cells, carrying proteins, lipids, and microRNA that they deliver to other cells. In skin, they have been reported to play a role in inflammation control, new blood vessel formation, extracellular matrix remodeling, pigment regulation, and hair follicle cycling. On mechanism alone, a role in regenerative aesthetic treatment sounds plausible.

The problem is the thinness of the human data. A literature review by Shah and colleagues, published in the Journal of Cosmetic Dermatology in 2025, found that early evidence supports efficacy for hair loss, facial rejuvenation, pigmentation, and scarring, while concluding that a lack of standardization in how exosomes are manufactured and applied currently limits their use. A separate review carried in the Journal of Drugs in Dermatology in January 2025 examined 56 papers published between 2014 and 2024 and itemized the same limitations: most of the available data is preclinical or early-stage, isolation and characterization methods differ from study to study, raw material sources vary widely enough to raise questions about potency and safety, and long-term clinical trials are still lacking.

A separate narrative review of dermatology literature from 2020 through 2025 describes a similar picture. Early human studies show an acceptable safety profile and a recurring pattern of benefit, but that benefit mostly appeared when exosomes were added on top of another treatment, such as microneedling, laser, or standard wound dressings, and product formulations, dosing, and outcome measures still vary too widely to compare directly.

Put together, exosomes today sit closer to an adjunct applied on top of another treatment than a standalone injection, and even that adjunct role is hard to compare across products. There is no established way to confirm that two products both labeled “exosome” actually contain the same thing.

The Regulatory Line in Korea

Korea adds one more condition on top of the science. The Ministry of Food and Drug Safety has stated that injecting a substance into skin for regeneration or wrinkle improvement is permitted only for products authorized as a drug or a medical device. A large share of the exosome products sold in Korea, however, are registered as cosmetics meant to be applied topically, and cosmetic registration in Korea does not require the safety and efficacy review that drug approval does.

A disciplinary case makes the boundary concrete. Korea’s Ministry of Health and Welfare suspended a physician’s license for three months in November 2023 under the Medical Service Act’s prohibition on unethical medical practice, after the physician injected a cosmetic-registered exosome product into a patient’s face. The physician argued that a product classified as a cosmetic could not be subject to that penalty, but Pharmnews reported that a court upheld the suspension in 2025. The ruling turned on a single principle: a product normally used topically that is instead administered by an invasive method must be treated, for regulatory purposes, as being used as a drug.

The drug pathway itself is still opening. Korea’s National Institute of Food and Drug Safety Evaluation issued guidance in late 2023 covering quality, non-clinical, and clinical evaluation for extracellular vesicle therapeutics, according to a 2025 report by Dailyvet, and the same report notes that no exosome product, formally an extracellular vesicle therapeutic, has yet received drug approval for human use in Korea.

This is why our skin booster lineup at UH CELL Gangnam is built from products operating inside that authorized category, including Rejuran, SKINVIVE, and Juvelook Volume. Our director, Dr. Kim Yeonjin, serves as an Allergan Aesthetics faculty member for Juvéderm and Botox and is registered as a Key Doctor for Potenza and Ulthera, and one thing that role makes clear again and again is that a product’s approval status is the actual boundary of what a treatment can be. When patients ask about continuing an exosome treatment they received or were offered abroad, we tell them upfront that this form of injection is not permitted here.

The Three Classes, Side by Side

	Hyaluronic Acid Class	Polynucleotide Class	Exosome
Typical form	Dermal microdroplet injection	Dermal injection, repeated every 4 weeks	Topical application or adjunct after another treatment
Target problem	Hydration, texture, radiance	Dermal density, fine lines, resilience	Regenerative signaling (research stage)
Published evidence	Randomized, evaluator-blinded pivotal trial: 58% improved at 1 month, 56% at 6 months (2023)	30 Asian participants followed 6 months (2024); systematic review of 9 studies, 219 participants (2025)	Early-stage and preclinical studies dominate; standardization still lacking (2025 reviews)
Injection status in Korea	Permitted within approved scope	Permitted within approved scope	Injecting cosmetic-registered products carries disciplinary risk
Evaluation point	1 month, 6 months	After full course, at 4 and 6 months	No standardized measure yet established

Figures in the table reflect the conditions of the specific product or study cited. Individual results vary with skin condition and treatment design.

Four Questions Worth Asking Before You Book

1. Ask what regulatory category the injected product falls under. Drug, medical device, or cosmetic. Anything going into the skin needs to be one of the first two.
2. Put the problem into one sentence before the consultation. “Rough texture and no glow” points to a different class than “thinner cheeks and more fine lines.”
3. Agree on the number of sessions and the evaluation date in advance. Polynucleotide treatments are usually designed as a series spaced four weeks apart, so if your stay in Seoul is short, decide during consultation how the first session here connects to any follow-up.
4. Keep a record of the treatment. Product name, dose, treatment area, and provider. That record matters later if you space out other procedures or need to discuss a reaction.

Fitting a Skin Booster Into a Short Stay

About 90 percent of our patients travel from outside Korea specifically for treatment, usually staying between two days and a week. Skin boosters fit that window comparatively well, since the main reactions are localized redness, minor swelling, and bruising rather than visible peeling. Swelling and marks the evening of treatment vary by person, so we recommend against scheduling a session immediately before an important event.

Our Gangnam location sits on the second and third floors of UH FLAT SIGNATURE Gangnam, so patients can go from treatment back to their room without leaving the building, and the oxygen chamber and vitamin IV drip are complimentary for hotel guests. Consultations and treatments take place in private rooms, and our Gangnam location keeps Japanese, Chinese, and English interpreters on staff. We cover how recovery splits between your stay and after you fly home in our guide to recovering from a skin procedure in Seoul.

FAQ

Can I get a hyaluronic acid booster and a polynucleotide booster on the same day?

There is no rule against combining them, and some treatment plans do pair them. But injecting both classes into the same area on the same day makes it hard to tell which one produced which change. If this is your first time trying either, we usually recommend starting with one class, checking how your skin responds, and deciding on the next step from there. Your treatment history and current skin condition affect this decision, so we work it out together in consultation.

How many sessions do I need, and when should I judge the result?

The Asian cohort study cited above used three injections at baseline, four weeks, and eight weeks, then evaluated at four and six months. The hyaluronic acid pivotal trial used one month and six months as its evaluation points. Both classes are designed to be judged in months, not days. Your actual session count depends on your skin and goals, and we set that during consultation.

Is it a problem if a clinic applies an exosome ampoule topically after a laser treatment?

Topical application sits within how cosmetics are meant to be used. The regulatory issue is injecting a topically registered product with a needle or another invasive device. Ask whether the product goes onto the skin or into it, and that answers the question.

Aren’t skin boosters basically the same thing as filler?

The ingredients can overlap while the goal stays distinct. Filler uses cross-linked hyaluronic acid placed in layers to build volume and shape a specific area. Skin boosters target skin quality markers like hydration, texture, and density. If what you actually want is to fill a hollow area, a skin booster will not do that, and we clarify this distinction early in consultation.

Preparing for Your Consultation

Sending us the products you currently use, any treatments from the past six months, and your planned dates in Seoul ahead of time lets us spend the consultation on diagnosis and planning rather than intake. Front and side photos taken in even lighting also help. You can reach UH CELL Gangnam to book or ask questions, and let us know your preferred consultation language so we can arrange the right interpreter in advance.